Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eOD-GT8 and Core-g28v2 mRNA Vaccines in Healthy Adults
NCT05001373Phase 1Active, not recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eOD-GT8 60mer mRNA vaccine and Core-g28v2 60mer mRNA vaccine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 9 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
eOD-GT8 60mer mRNA vaccineCore-g28v2 60mer mRNA vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05001373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001373.